58 Investors following Arch Pharmalabs. Share this News with them.
0
Like this story, share it with millions of investors on M3
Arch Pharmalabs gets verification mark from USP (PIVP)
Arch Pharmalabs Ltd, a leading supplier of API (Active Pharmaceuticals Ingredients) and Intermediates, announced that it has received a new verification mark for a drug substance from US Pharmacopeia (USP) under the Pharmaceutical Ingredient Verification Program (PIVP) at their Gurgaon manufacturing facility.
Arch Pharmalabs Ltd, a leading supplier of API (Active Pharmaceuticals Ingredients) and Intermediates, today announced that it has received a new verification mark for a drug substance from US Pharmacopeia (USP) under the Pharmaceutical Ingredient Verification Program (PIVP) at their Gurgaon manufacturing facility.
USP created the PIVP as an independent, ethical, and credible third party verification for quality compliance thus adding one more element of safety and comfort for manufacturers and their customers. This was done to address increasing concerns throughout the pharmaceutical industry about the quality and consistency of pharmaceutical ingredients.
The programme enables manufacturers to showcase their quality and integrity of their products with a recognizable 'USP Verified' mark'. Arch Pharmalabs has received this verification for Clopidogrel Bisulfate (Form1). This mark can be used by Arch Pharmalabs on the certificate of analysis and other bulk-label containers of this product.
Commenting on this development, Mr. Ajit Kamath, CMD, Arch Pharmalabs Ltd. said "This USP verification mark signifies our commitment to the very stringent processes and quality standards we follow at Arch Pharmalabs. We have undergone rigorous and independent conformity assessments to receive this certification. We further, look forward to working closely, with USP PIVP and exposing our other products to this respectful certification".
